MyAverix Finance MyAverix Finance

TW · Healthcare

Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)

Biotechnology

Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) is listed on TW in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 1762

P/E ratio
25.00

Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) — FAQ

What is 1762's P/E ratio?

The price-to-earnings (P/E) ratio for Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) is 25.00 (data as of 2026-05-23).

Does Chunghwa Chemical Synthesis & Biotech Co Ltd pay a dividend?

Dividend yield is not available in the current snapshot for Chunghwa Chemical Synthesis & Biotech Co Ltd (1762). Check the MyAverix Finance app for the latest dividend data.

What sector is Chunghwa Chemical Synthesis & Biotech Co Ltd in?

Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) is classified in the Healthcare sector (Biotechnology industry).

What exchange is 1762 listed on?

1762 is listed on TW.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play